Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Blog

Wall Street Bulls Look Optimistic About SharkNinja, Inc. (SN): Should You Buy?
Wall Street Bulls Look Optimistic About SharkNinja, Inc. (SN): Should You Buy?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm

Brokers Suggest Investing in Gray Media (GTN): Read This Before Placing a Bet
Brokers Suggest Investing in Gray Media (GTN): Read This Before Placing a Bet

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)

Is It Worth Investing in MINISO Group Holding Limited (MNSO) Based on Wall Street's Bullish Views?
Is It Worth Investing in MINISO Group Holding Limited (MNSO) Based on Wall Street's Bullish Views?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm

Is It Worth Investing in Cisco (CSCO) Based on Wall Street's Bullish Views?
Is It Worth Investing in Cisco (CSCO) Based on Wall Street's Bullish Views?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)

Urogen Pharma (URGN) Reports Q1 Loss, Beats Revenue EstimatesPhoto, wide shot, wide-angle lens,  Clinical research organization, sunset photo at golden hour, photo by Peter Lik: https://img.midjourneyapi.xyz/temp/02f7778c-d723-4fb3-bdef-fabb7e5fc9c8.png
Urogen Pharma (URGN) Reports Q1 Loss, Beats Revenue Estimates

Urogen Pharma (URGN) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.92 per share a year ago. These figures

Here's What Key Metrics Tell Us About Amcor (AMCR) Q3 Earnings
Here's What Key Metrics Tell Us About Amcor (AMCR) Q3 Earnings

For the quarter ended March 2026, Amcor (AMCR) reported revenue of $5.91 billion, up 77.4% over the same period last year. EPS came in at $0.96, compared to $0.90 in the year-ago quarter.

The

Trinity Capital (TRIN) Surpasses Q1 Earnings and Revenue Estimates
Trinity Capital (TRIN) Surpasses Q1 Earnings and Revenue Estimates

Trinity Capital (TRIN) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.52 per share a year ago. These

Bloomin' Brands (BLMN) Reports Q1 Earnings: What Key Metrics Have to Say
Bloomin' Brands (BLMN) Reports Q1 Earnings: What Key Metrics Have to Say

For the quarter ended March 2026, Bloomin' Brands (BLMN) reported revenue of $1.06 billion, up 1% over the same period last year. EPS came in at $0.67, compared to $0.59 in the year-ago quarter.

The

Brokers Suggest Investing in Chewy (CHWY): Read This Before Placing a Bet
Brokers Suggest Investing in Chewy (CHWY): Read This Before Placing a Bet

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts

Is It Worth Investing in Datadog (DDOG) Based on Wall Street's Bullish Views?
Is It Worth Investing in Datadog (DDOG) Based on Wall Street's Bullish Views?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)

F5 (FFIV) Reports Q2 Earnings: What Key Metrics Have to Say
F5 (FFIV) Reports Q2 Earnings: What Key Metrics Have to Say

For the quarter ended March 2026, F5 Networks (FFIV) reported revenue of $811.7 million, up 11% over the same period last year. EPS came in at $3.90, compared to $3.42 in the year-ago quarter.

The

One Stop Systems, Inc. (OSS) Beats Q1 Earnings and Revenue Estimates
One Stop Systems, Inc. (OSS) Beats Q1 Earnings and Revenue Estimates

One Stop Systems, Inc. (OSS) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to a loss of $0.07 per share a year

Compared to Estimates, Dine Brands (DIN) Q1 Earnings: A Look at Key Metrics
Compared to Estimates, Dine Brands (DIN) Q1 Earnings: A Look at Key Metrics

For the quarter ended March 2026, Dine Brands (DIN) reported revenue of $225.2 million, up 4.9% over the same period last year. EPS came in at $1.07, compared to $1.03 in the year-ago quarter.

The

Is It Worth Investing in Palantir Technologies (PLTR) Based on Wall Street's Bullish Views?
Is It Worth Investing in Palantir Technologies (PLTR) Based on Wall Street's Bullish Views?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)

MPLX LP (MPLX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
MPLX LP (MPLX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

MPLX LP (MPLX) reported $3.04 billion in revenue for the quarter ended March 2026, representing a year-over-year decline of 2.8%. EPS of $0.90 for the same period compares to $1.10 a year ago.

The

New York Times (NYT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
New York Times (NYT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended March 2026, New York Times Co. (NYT) reported revenue of $712.24 million, up 12% over the same period last year. EPS came in at $0.61, compared to $0.41 in the year-ago

Novavax (NVAX) Reports Q1 Loss, Beats Revenue Estimates
Novavax (NVAX) Reports Q1 Loss, Beats Revenue Estimates

Novavax (NVAX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to earnings of $2.93 per share a year ago. These figures are

Is It Worth Investing in Petrobras (PBR) Based on Wall Street's Bullish Views?
Is It Worth Investing in Petrobras (PBR) Based on Wall Street's Bullish Views?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)

APTIV PLC (APTV) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
APTIV PLC (APTV) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Aptiv PLC (APTV) reported $5.09 billion in revenue for the quarter ended March 2026, representing a year-over-year increase of 5.4%. EPS of $1.71 for the same period compares to $1.69 a year ago.

Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Tops Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Tops Revenue Estimates

Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.7 per share a year ago

Brokers Suggest Investing in Nu  (NU): Read This Before Placing a Bet
Brokers Suggest Investing in Nu (NU): Read This Before Placing a Bet

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)

fuboTV Inc. (FUBO) Reports Q2 Loss, Lags Revenue Estimates
fuboTV Inc. (FUBO) Reports Q2 Loss, Lags Revenue Estimates

fuboTV Inc. (FUBO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.24 per share a year ago. These figures are

Here's What Key Metrics Tell Us About IQVIA (IQV) Q1 Earnings
Here's What Key Metrics Tell Us About IQVIA (IQV) Q1 Earnings

For the quarter ended March 2026, IQVIA Holdings (IQV) reported revenue of $4.15 billion, up 8.4% over the same period last year. EPS came in at $2.90, compared to $2.70 in the year-ago quarter.

The

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue EstimatesPhoto, wide shot, wide-angle lens,  Mental health care service, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ce3b930-5e2a-4215-b686-0ad0eb0b922a.png
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates

BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of $0.06. This compares to break-even earnings per share a year ago. These

Solventum (SOLV) Recently Broke Out Above the 50-Day Moving Average
Solventum (SOLV) Recently Broke Out Above the 50-Day Moving Average

From a technical perspective, Solventum (SOLV) is looking like an interesting pick, as it just reached a key level of support. SOLV recently overtook the 50-day moving average, and this suggests a